EIF2AK3 and cancer: Given that the PERK arm of the UPR is also activated in cancer (63, 82, 83) and that both ECD and GRP78 are overexpressed in cancer (69, 70, 76, –, 81), we suggest that ECD overexpression may play a similar role to mitigate the negative consequences of elevated PERK signaling found in cancer.